Nurix Therapeutics Inc (NRIX) - News Archive

Nurix Therapeutics has recently made significant strides in the field of oncology and immunology with their pioneering research and development programs. Building upon a series of compelling studies and validatory precl...

Nurix Therapeutics Unveils Groundbreaking Preclinical Data at AACR 2025: Orally Available Degraders Show Promise Against Key Oncology TargetsIn an exciting development set to transform the landscape of oncology treatmen...

Nurix Therapeutics Strengthens Workforce Amid Financial Challenges with Inducement Grants: A Strategic Move Towards Innovation in Targeted Protein Degradation MedicinesOn April 11, 2025, Nurix Therapeutics, Inc. (Nasdaq...

Assessing Nurix Therapeutics’ Inducement Grants and Financial LandscapeOverview of Recent Developments:In early March 2025, Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializin...

In a strategic maneuver aimed at solidifying its talent pool, Nurix Therapeutics, Inc. (Nasdaq: NRIX), a pioneering force in the field of targeted protein degradation medicines, announced on February 14, 2025, the grant...

In a significant strategic update, Nurix Therapeutics Inc. has laid out its ambitious goals for 2025, focusing on advancing its robust pipeline targeted at revolutionizing treatment for cancer and autoimmune diseases. O...

In an exciting development for patients battling relapsed or refractory Waldenstrom’s macroglobulinemia, Nurix Therapeutics Inc. has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for i...

Chronic lymphocytic leukemia (CLL), a common type of leukemia in adults, presents significant treatment challenges, particularly in patients who are pretreated or have developed resistance to conventional therapies. The...

: Nurix Therapeutics has announced that its investigational drug NX-5948 has received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA). This designation is aimed at facilitating the develo...

:Nurix Therapeutics recently presented favorable outcomes from an ongoing clinical trial investigating the efficacy of NX-5948 in patients with relapsed refractory Chronic Lymphocytic Leukemia (CLL) at the European Hema...

San Francisco, CA - Nurix Therapeutics, a company at the forefront of small molecule therapeutics, has announced that it will host a webcast and conference call to discuss pivotal data from its ongoing Phase 1 clinical...

Nurix Therapeutics, a pioneer in the field of targeted protein modulation, has announced a forthcoming oral presentation revealing fresh data from the ongoing clinical trial of NX-5948, a selective Bruton s Tyrosine Kin...

Following the recent announcement from Nurix Therapeutics Inc. regarding the closing of its public offering and full exercise of underwriters option to purchase additional shares, it is important to analyze the impact o...

Nurix Therapeutics, a leading biotech company based in San Francisco, recently announced the pricing of its upsized underwritten public offering of common stock. The company’s successful offering, which totaled $175 mil...

Nurix Therapeutics Announces Proposed Public Offering Amidst Challenging Financial PerformanceSAN FRANCISCO, April 11, 2024 - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializ...

In a major development for the field of oncology, Nurix Therapeutics recently announced the lifting of a partial clinical hold on its Phase 1a/1b study of NX-2127. The U.S. Food and Drug Administration (FDA) has granted...

In a groundbreaking development, Nurix Therapeutics has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate NX-5948, aimed at treating patients with relapsed or refr...

Nurix Therapeutics, a biopharmaceutical company focused on targeted protein modulation for the treatment of cancer and autoimmune diseases, has recently outlined its 2024 strategic priorities. The company plans to advan...

In the rapidly evolving world of medical therapeutics, Nurix Therapeutics Inc has made significant strides forward with its novel Bruton s Tyrosine Kinase (BTK) degrader programs, NX-5948 and NX-2127. Evidence of this o...

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual MeetingSAN FRANCISCO, Dec. 04...